Within three months before death, most of the residents in our research underwent burdensome interventions of questionable benefit. However, when health care proxies were alert to the indegent prognosis and the anticipated clinical complications, residents were less likely to undergo these interventions in the final days of life. Our study corroborates and extends prior research showing high mortality rates among sufferers with advanced dementia.10,11,20-22 With a 6-month mortality price of 25 percent and a median survival of just one 1.3 years, advanced dementia is associated with a life expectancy similar to that for additionally recognized end-of-life conditions, such as metastatic breast cancer23 and stage IV congestive heart failure.24 The idea that dementia is a terminal illness is further supported by our finding that the majority of the deaths were not precipitated by devastating acute events , other terminal diseases , or the decompensation of chronic circumstances .Steep charges for AIDS drugs have already been criticized by sufferers and advocacy groups, who say they deter use of lifesaving medications. In 2004, Roche & Trimeris created an international uproar when its medication Fuzeon, trusted as another or third-line salvage therapy also, was first introduced and priced at $20,000 USD per year, per patient–far above what analysts had expected. AHF’s Weinstein added, AIDS drugs will set you back the maximum the market will bear, of production costs regardless. Other drug makers continue to follow suit with high prices similarly, and usage of care and treatment is the casualty. We problem both Merck and the pharmaceutical industry as a whole to set pricing and access plans for these potentially lifesaving AIDS drugs in a fashion that illustrates its concern for patient standard of living, rather than contributing to the public’s growing crisis of confidence in it.